Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant therapy with FOLFIRINOX and/or gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer

Next Previous
Trial Profile

Neoadjuvant therapy with FOLFIRINOX and/or gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 20 Mar 2017 New trial record
    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top